UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Definitions and Diagnosis of Pulmonary Hypertension

Journal of the American College of Cardiology, 2013-12, Vol.62 (25), p.D42-D50

2013

Volltextzugriff (PDF)

Updated Clinical Classification of Pulmonary Hypertension

Journal of the American College of Cardiology, 2009-06, Vol.54 (1), p.S43-S54

2009

Volltextzugriff (PDF)

Riociguat: Mode of Action and Clinical Development in Pulmonary Hypertension

Chest, 2017-02, Vol.151 (2), p.468-480

2017

Volltextzugriff (PDF)

Pulmonary Capillary Hemangiomatosis

Chest, 2014-02, Vol.145 (2), p.197-199

Langleben, David, MD

2014

Volltextzugriff (PDF)

Combination Therapy for Pulmonary Arterial Hypertension: A Systematic Review and Meta-analysis

Canadian journal of cardiology, 2016-12, Vol.32 (12), p.1520-1530

2016

Volltextzugriff (PDF)

Meta-Analysis of Monotherapy Versus Combination Therapy for Pulmonary Arterial Hypertension

The American journal of cardiology, 2011-10, Vol.108 (8), p.1177-1182

2011

Volltextzugriff (PDF)

EPITOME-2: An open-label study assessing the transition to a new formulation of intravenous epoprostenol in patients with pulmonary arterial hypertension

The American heart journal, 2014-02, Vol.167 (2), p.210-217

2014

Volltextzugriff (PDF)

Incidence and Significance of Pericardial Effusion in Patients With Pulmonary Arterial Hypertension

Canadian journal of cardiology, 2013-06, Vol.29 (6), p.678-682

2013

Volltextzugriff (PDF)

The Relationship Between NO Pathway Biomarkers and Response to Riociguat in the RESPITE Study of Patients With PAH Not Reaching Treatment Goals With Phosphodiesterase 5 Inhibitors

Chest, 2016-10, Vol.150 (4), p.1316A-1316A

2016

Volltextzugriff (PDF)

Usefulness of Right Ventricular Dysfunction to Predict New-Onset Atrial Fibrillation Following Coronary Artery Bypass Grafting

The American journal of cardiology, 2014-03, Vol.113 (6), p.913-918

2014

Volltextzugriff (PDF)

From the Echo Bed to the Pulmonary Vascular Bed

Chest, 2014-10, Vol.146 (4), p.876-878

2014

Volltextzugriff (PDF)

Endothelin Receptor Antagonists in the Treatment of Pulmonary Arterial Hypertension

Clinics in chest medicine, 2007-03, Vol.28 (1), p.117-125

Langleben, David, MD, FRCPC

2007

Volltextzugriff (PDF)

Prevalence and Impact of Coronary Artery Disease in Patients With Pulmonary Arterial Hypertension

The American journal of cardiology, 2011-08, Vol.108 (3), p.460-464

2011

Volltextzugriff (PDF)

Use of clinically relevant responder threshold criteria to evaluate the response to treatment in the Phase III PATENT-1 study

The Journal of heart and lung transplantation, 2015-03, Vol.34 (3), p.338-347

2015

Volltextzugriff (PDF)

The Use of Antidepressants and the Risk of Idiopathic Pulmonary Arterial Hypertension

Canadian journal of cardiology, 2014-12, Vol.30 (12), p.1633-1639

2014

Volltextzugriff (PDF)

Comparison of hemodynamic parameters in treatment-naïve and pretreated patients with pulmonary arterial hypertension in the randomized Phase III PATENT-1 study

The Journal of heart and lung transplantation, 2016

2016

Volltextzugriff (PDF)

Long-term Riociguat Treatment in PAH Patients in WHO Functional Class (FC) I/II Versus FC III/IV at Baseline: Results From the 12-Week Phase III PATENT-1 Study and PATENT-2 Open-Label Extension

Chest, 2014-03, Vol.145 (3), p.513A-1-513A-3

2014

Volltextzugriff (PDF)

Riociguat for the Treatment of Pulmonary Arterial Hypertension: A Randomized, Double-Blind, Placebo-Controlled Study (PATENT-1)

Chest, 2012-10, Vol.142 (4), p.1027A-1027D

2012

Volltextzugriff (PDF)

Hemodynamic Stability After Transitioning Between Endothelin Receptor Antagonists in Patients With Pulmonary Arterial Hypertension

Canadian journal of cardiology, 2013-06, Vol.29 (6), p.672-677

2013

Volltextzugriff (PDF)

Right Ventricular End-Diastolic Wall Stress Predicts Survival in Patients With Pulmonary Arterial Hypertension

Chest, 2013, Vol.144 (4), p.869A-869A

2013

Volltextzugriff (PDF)

Riociguat for the Treatment of Pulmonary Arterial Hypertension (PAH): 1-Year Results from the PATENT-2 Long-term Extension Study

Chest, 2013, Vol.144 (4), p.1024A-1024B

2013

Volltextzugriff (PDF)

Predictors of long-term outcomes in patients treated with riociguat for pulmonary arterial hypertension: data from the PATENT-2 open-label, randomised, long-term extension trial

The lancet respiratory medicine, 2016-05, Vol.4 (5), p.361-371

2016

Volltextzugriff (PDF)

Tadalafil monotherapy and as add-on to background bosentan in patients with pulmonary arterial hypertension

The Journal of heart and lung transplantation, 2011-06, Vol.30 (6), p.632-643

2011

Volltextzugriff (PDF)

Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. A randomized, controlled trial

Annals of internal medicine, 2000-03, Vol.132 (6), p.425

2000

Volltextzugriff (PDF)

A Comparison of Continuous Intravenous Epoprostenol (Prostacyclin) with Conventional Therapy for Primary Pulmonary Hypertension

The New England journal of medicine, 1996-02, Vol.334 (5), p.296-301

1996

Volltextzugriff (PDF)

1 – 25 von 26

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(26)
Mit Volltextzugriff
(24)

Publikationsform

Artikel
(24)
Tagungsberichte
(2)

Sprache

Englisch
(26)

Erscheinungsjahr

n.n

Thema

Humans
(17)
Life Sciences & Biomedicine
(17)
Science & Technology
(17)
Cardiac & Cardiovascular Systems
(12)
Cardiovascular System & Cardiology
(12)
Female
(11)
Hypertension, Pulmonary - Drug Therapy
(11)
Cardiovascular
(10)
Male
(10)
Middle Aged
(10)
Pulmonary/respiratory
(10)
Treatment Outcome
(10)
Aged
(7)
Biological And Medical Sciences
(7)
Medical Sciences
(7)
Adult
(6)
Antihypertensive Agents - Administration & Dosage
(5)
Follow-Up Studies
(5)
Hypertension, Pulmonary - Physiopathology
(5)
Respiratory System
(5)

15 weitere anzeigen...

Weniger anzeigen...

Kollektion

IngentaConnect Journals
(19)
MEDLINE
(17)
Publisher or Other Site
(17)
EZB Free E-Journals
(16)
Journals@Ovid Complete
(15)
Elsevier ScienceDirect Journals Complete
(14)
Elsevier Journal Backfiles on ScienceDirect (DFG Nationallizenzen)
(4)
IngentaConnect Journals
(1)

3 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Definitions and Diagnosis of Pulmonary Hypertension

Updated Clinical Classification of Pulmonary Hypertension

Riociguat: Mode of Action and Clinical Development in Pulmonary Hypertension

Pulmonary Capillary Hemangiomatosis

Combination Therapy for Pulmonary Arterial Hypertension: A Systematic Review and Meta-analysis

Meta-Analysis of Monotherapy Versus Combination Therapy for Pulmonary Arterial Hypertension

EPITOME-2: An open-label study assessing the transition to a new formulation of intravenous epoprostenol in patients with pulmonary arterial hypertension

Incidence and Significance of Pericardial Effusion in Patients With Pulmonary Arterial Hypertension

The Relationship Between NO Pathway Biomarkers and Response to Riociguat in the RESPITE Study of Patients With PAH Not Reaching Treatment Goals With Phosphodiesterase 5 Inhibitors

Usefulness of Right Ventricular Dysfunction to Predict New-Onset Atrial Fibrillation Following Coronary Artery Bypass Grafting

From the Echo Bed to the Pulmonary Vascular Bed

Endothelin Receptor Antagonists in the Treatment of Pulmonary Arterial Hypertension

Prevalence and Impact of Coronary Artery Disease in Patients With Pulmonary Arterial Hypertension

Use of clinically relevant responder threshold criteria to evaluate the response to treatment in the Phase III PATENT-1 study

The Use of Antidepressants and the Risk of Idiopathic Pulmonary Arterial Hypertension

Comparison of hemodynamic parameters in treatment-naïve and pretreated patients with pulmonary arterial hypertension in the randomized Phase III PATENT-1 study

Long-term Riociguat Treatment in PAH Patients in WHO Functional Class (FC) I/II Versus FC III/IV at Baseline: Results From the 12-Week Phase III PATENT-1 Study and PATENT-2 Open-Label Extension

Riociguat for the Treatment of Pulmonary Arterial Hypertension: A Randomized, Double-Blind, Placebo-Controlled Study (PATENT-1)

Hemodynamic Stability After Transitioning Between Endothelin Receptor Antagonists in Patients With Pulmonary Arterial Hypertension

Right Ventricular End-Diastolic Wall Stress Predicts Survival in Patients With Pulmonary Arterial Hypertension

Riociguat for the Treatment of Pulmonary Arterial Hypertension (PAH): 1-Year Results from the PATENT-2 Long-term Extension Study

Predictors of long-term outcomes in patients treated with riociguat for pulmonary arterial hypertension: data from the PATENT-2 open-label, randomised, long-term extension trial

Tadalafil monotherapy and as add-on to background bosentan in patients with pulmonary arterial hypertension

Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. A randomized, controlled trial

A Comparison of Continuous Intravenous Epoprostenol (Prostacyclin) with Conventional Therapy for Primary Pulmonary Hypertension

Suchergebnisse filtern